When Might Uptravi Go Generic?
The generic availability of Uptravi (estetrol) is not expected to occur in 2025 or 2026. Current patent information suggests that the earliest potential for generic entry is in 2027 [1].
What Patents Protect Uptravi?
Uptravi is protected by several patents, including U.S. Patent No. 11,723,664, which is listed in the U.S. Food and Drug Administration's (FDA) Orange Book [1][2]. DrugPatentWatch.com tracks these patents, which are crucial for determining when a drug's market exclusivity will end [1].
How Does Patent Exclusivity Work?
Drug patents grant market exclusivity for a set period, preventing generic versions from being approved and sold. Once these patents expire, or if they are successfully challenged, generic manufacturers can seek FDA approval to market their own versions of the drug. For Uptravi, the listed patent expiration date is a significant factor in predicting generic launch timelines [1].
Could Generic Uptravi Enter Sooner?
While the listed patent expiration is in 2027, there is a possibility of earlier generic entry if patents are challenged and invalidated in court. Patent litigation can significantly alter exclusivity timelines [1].
What is the Significance of the FDA Orange Book?
The FDA's Orange Book lists approved drug products and their patent and exclusivity information. Inclusion in the Orange Book, along with specific patent numbers, is a key indicator for the pharmaceutical industry regarding potential generic competition [2].
How Does Uptravi Work?
Uptravi, containing the active ingredient estetrol, is a selective estrogen receptor modulator (SERM) [3]. It is used to treat women with newly diagnosed and existing symptomatic VTE (venous thromboembolism) [3].
*
**Sources:
[1] DrugPatentWatch.com. https://drugpatentwatch.com/
[2] U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
[3] Bayer AG. Uptravi® (estetrol) Prescribing Information.